does semaglutide make you moody Penn study focuses on and mental health impacts The Pros and Cons of

Robert Kushner , a professor of medicine and medical education at Northwestern University, who led the Novo Nordisk-funded phase 3 clinical trial

The SELECT trial, which included 17,604 participants with established cardiovascular disease, found that semaglutide (Wegovy) reduced the risk of major adverse cardiovascular events (MACE) by 20% compared with placebo

People in the semaglutide group also lost weight and had better results on blood tests related to liver function

Some telltale signs of progress include: Though most people can expect modest weight loss with a low dose of Wegovy, the medication's effects are dose-dependent

Immune Support : By regulating the immune response and reducing inflammation, glutathione helps the body defend against pathogens and diseases